

Selected Innovative Medicines in Development as of October 17, 2023



Oncology (1 of 2)

TALVEY (talquetamab)

Relapsed Refractory Multiple Myeloma

BALVERSA (erdafitinib)

Urothelial cancer (THOR)

RYBREVANT (amivantamab)

Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

TECVAYLI (teclistamab)

Multiple Myeloma 1-3PLs (MajesTEC-3)

amivantamab / lazertinib

Non Small Cell Lung Cancer (MARIPOSA)

TAR-200 (RIS/gemcitabine plus cetrelimab)

Muscle invasive bladder cancer (SunRISe-2)

DARZALEX (daratumumab)

Smoldering multiple myeloma (SMM3001)

CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma TNI (CARTITUDE-5)

AKEEGA (niraparib/abiraterone)

L1 Prostate cancer metastatic castration-resistant (MAGNITUDE)

ERLEADA (apalutamide)

Tablet Reduction

TECVAYLI (teclistamab)

Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

TALVEY (talquetamab)

Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumentAL-3)

IMBRUVICA (ibrutinib)

Relapsed Refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant eligible (PERSEUS)

ERLEADA (apalutamide)

High risk prostate cancer (PROTEUS)

RYBREVANT (amivantamab)

Subcutaneous (PALOMA-3)

IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4)

TECVAYLI (teclistamab)

TE NDMM maintenance (MajesTEC-4)

AKEEGA (niraparib/abiraterone)

M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

TAR-200 (RIS/gemcitabine plus cetrelimab)

Non muscle invasive bladder cancer BCG-naïve High Risk (SunRISe-3)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible (CEPHEUS)

ERLEADA (apalutamide)

Localized prostate cancer (ATLAS)

amivantamab / lazertinib

Non Small Cell Lung Cancer 2L (MARIPOSA-2)

TAR-200 (RIS/gemcitabine plus cetrelimab)

Non muscle invasive bladder cancer (SunRISe-1)

JNJ-8343

Prostate Cancer

JNJ-8543

Hematological Malignancies

JNJ-8780

Hematological Malignancies

JNJ-4681

Hematological Malignancies

BALVERSA (erdafitinib)

Non muscle invasive bladder cancer

VAC85135

Hematological Malignancies

JNJ-8114

Prostate Cancer

JNJ-6617

Hematological Malignancies

BALVERSA (erdafitinib)

Tumor Agnostic

erdafitinib

Intravesical Delivery System for Localized Bladder Cancer

JNJ-5322

Multiple Myeloma

JNJ-6420

Prostate Cancer

STELARA (ustekinumab)

Pediatric Juvenile Psoriatic Arthritis

TREMFYA (guselkumab)

Psoriatic Arthritis Structural Damage

TREMFYA (guselkumab)

Crohn's Disease (GALAXI)

SIMPONI (golimumab)

Pediatric Ulcerative Colitis

nipocalimab

Idiopathic inflammatory myopathy

nipocalimab

Systemic Lupus Erythematosus

Combination Therapy

Psoriatic Arthritis

JNJ-4703

Atopic Dermatitis

TREMFYA (guselkumab)

Ulcerative Colitis Subcutaneous Induction (ASTRO)

TREMFYA (guselkumab)

Ulcerative Colitis Monotherapy (QUASAR)

STELARA (ustekinumab)

Pediatric Ulcerative Colitis

nipocalimab

Warm Autoimmune Hemolytic Anemia

nipocalimab

Hemolytic Disease of the Fetus and Newborn

nipocalimab Combination Therapy

Rheumatoid Arthritis

JNJ-4804 Combination Therapy

Ulcerative Colitis

JNJ-1459

Psoriasis

TREMFYA (guselkumab)

Crohn's Disease Subcutaneous Induction (GRAVITI)

TREMFYA (guselkumab)

Pediatric Psoriasis

STELARA (ustekinumab)

Pediatric Crohn's Disease

TREMFYA (guselkumab)

Giant Cell Arteritis

nipocalimab

Sjogren's Syndrome

JNJ-4804 Combination Therapy

Crohn's Disease

JNJ-2113

Psoriasis

JNJ-9280

Inflammatory Bowel Disease

JNJ-4703

Rheumatoid Arthritis

Cardiovascular and Metabolism

AAV-RPGR

Retinitis Pigmentosa

Milvexian (Factor Xla)

Secondary Stroke Prevention

AAV-CNGA3

Achromatopsia

Milvexian (Factor Xla)

Atrial Fibrillation

JNJ-1887

Dry Age-Related Macular Degeneration

JNJ-0237

Autosomal Dominant Polycystic Kidney Disease

Milvexian (Factor Xla)

Acute Coronary Syndrome

AAV-CNGB3

Achromatopsia

Pulmonary Hypertension

OPSUMIT (macitentan)

Pediatric pulmonary arterial hypertension

macitentan

Pulmonary arterial hypertension 75mg (UNISUS)

macitentan w/tadalafil FDC

Pulmonary arterial hypertension

prostacyclin receptor agonist

Pulmonary arterial hypertension

UPTRAVI (selexipag)

Pediatric pulmonary arterial hypertension

Infectious Diseases and Vaccines, Global Public Health

CABENUVA

HIV Adolescents

VAC31518

Janssen COVID-19 Vaccine

JNJ-1802

Dengue Prophylaxis

VAC52150

Monovalent Ebola Virus Vaccine

REMICADE (Infliximab)

COVID-19

EDURANT (rilpivirine)

HIV pediatric 2-12 year old

VAC52416

Multivalent ExPEC Vaccine

seltorexant

Adjunctive treatment for major depressive disorder with insomnia symptoms

aticaprant

Adjunctive Major Depressive Disorder

nipocalimab

Generalized Myasthenia Gravis Pediatrics

JNJ-1813

Epilepsy

nipocalimab

Chronic Inflammatory Demyelinating Polyneuropathy

seltorexant

Probable Alzheimer's with clinically significant agitation/aggression

SPRAVATO (esketamine)

Major Depressive Disorder with Suicidal Ideation Pediatrics

JNJ-0376

Parkinson's Disease

nipocalimab

Generalized Myasthenia Gravis

anti-phospho-tau mAb

Alzheimer's Disease

P2X7 antagonist

Bipolar Depression

VAC20121 *

Alzheimer's Disease

*This information is as of October 17, 2023 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. *AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements - XARELTO: Bayer; milvexian: Bristol Myers Squibb; apocritentan: Idorsia; X-Linked Retinitis Pigmentosa (AAV-RPGR) and Achromatopsia Gene Therapies (CNGA3 and CNGB3): MeiraGTx; JNJ-1887: Hemera Biosciences; PNPLA3: Arrowhead Pharmaceuticals; COMPLERA / EVIPLERA, ODEFSEY, SYMTUZA, PREZCOBIX / REZOLSTA FDC: Gilead Sciences; JULUCA and Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; COVID-19 vaccine: funded in part with federal funds from the U.S. Department of Health and Human Services; Cloudbreak antiviral conjugates (AVCs); ExPEC: GSK; REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113, JNJ-4238 and JNJ-5186: Protagonist Therapeutics; Tau Vaccine: AC Immune SA; JNJ-1813: Addex Pharmaceuticals; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; VELCADE: Millennium, The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO; Genmab A/S; BALVERSA: Astex Pharmaceuticals; ERLEADA: Regents of California and Memorial Sloan Kettering; cilta-cel: Legend Biotech; niraparib: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); Janssen's Monovalent Ebola Vaccine: Bavarian Nordic A/S, NIAID, IMI2, EFPIA, BARDA, NIH; Filovirus multivalent vaccine: Bavarian Nordic